Xeris Biopharma (XERS) to Release Earnings on Friday

Xeris Biopharma (NASDAQ:XERS) is scheduled to post its quarterly earnings results before the market opens on Friday, November 8th. Analysts expect Xeris Biopharma to post earnings of ($0.09) per share for the quarter. Xeris Biopharma has set its FY 2024 guidance at EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.01. The firm had revenue of $48.07 million during the quarter, compared to analyst estimates of $46.80 million. Xeris Biopharma had a negative return on equity of 16,662.63% and a negative net margin of 32.83%. During the same quarter in the previous year, the business earned ($0.14) EPS. On average, analysts expect Xeris Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Xeris Biopharma Price Performance

Shares of NASDAQ:XERS opened at $3.26 on Wednesday. The business’s 50 day moving average price is $2.93 and its 200-day moving average price is $2.47. The firm has a market capitalization of $485.74 million, a price-to-earnings ratio of -7.58 and a beta of 2.70. Xeris Biopharma has a 1 year low of $1.46 and a 1 year high of $3.39.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Xeris Biopharma in a research note on Thursday, August 15th.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.